News

According to the renewed deal, Novamed Pharmaceuticals, a wholly owned subsidiary of SciClone, will promote the products in the region till 31 December 2013 with a possibility of

Under the deals, Oxford will have access to Lophius’ UREA technology while Lophius will gain access to Oxford’s T-SPOT technology. Oxford chief executive officer Dr. Peter Wrighton-Smith said,

Caldolor (ibuprofen) Injection, which features analgesic, antipyretic and anti-inflammatory properties, is indicated for pain and fever in the hospital setting. Cumberland Pharmaceuticals chief executive officer A.J. Kazimi said,

Minivelle, which the company claims is the smallest estrogen patch, is bioequivalent to company’s Vivelle, (estradiol transdermal system) and is 34% smaller than Vivelle-Dot. The company said Minivelle,

Total revenue for fourth quarter of 2012 was $5.96bn compared to $6.05bn for the fourth quarter of 2011. The company reported a net income of $4.09bn, or $3.66

The JV will formulate Leuprolide in a proprietary controlled-release drug delivery platform technology, developed by Foresee. Under the JV, ScinoPharm will act as the exclusive provider of Leuprolide

Under the deal, Afraxis will earn around $187.5m in total as upfront, research, development and commercialization milestone payments. Afraxis president and CEO and Avalon Ventures managing partner Jay

The completion of cGMP manufacturing, which resulted in a high yield batch of DM-199, allows the company to use DM-199 compound in its upcoming clinical trials. The company

The partnership will focus on developing and validating the diagnostic EP-AD assay for use as both a biomarker, useful in AD related clinical studies, and an FDA-approved AD